Use of ginsenosides Rh2, Ck and Rg3 in increasing myocardial contractility

A ginsenoside, myocardial contraction technology, applied in the field of Ck and Rg3 to increase myocardial contractility, in the field of ginsenoside Rh2, can solve problems such as large differences

Inactive Publication Date: 2006-12-20
彭康康
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This is quite different from the traditional efficacy of ginseng

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of ginsenosides Rh2, Ck and Rg3 in increasing myocardial contractility
  • Use of ginsenosides Rh2, Ck and Rg3 in increasing myocardial contractility

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Embodiment 1, frog heart isolated perfusion experiment

[0015] 1. Experimental animals and reagents 40 toads, male or female, weighing 80-100 g, were provided by the Experimental Animal Center of Qingdao Medical College. Each ginsenoside injection was provided by Dalian Qidong Pharmaceutical Research Institute. The toads were randomly divided into 4 groups, namely the ginsenoside CK group, the ginsenoside Rh group, and the ginsenoside Rh group. 2 Ginsenoside Rg 3 Ginsenoside Rb 1 Group, 10 in each group.

[0016] 2. For the preparation of isolated toad heart specimens, refer to Xu Shuyun's "Pharmacological Experimental Methodology" (People's Health Publishing House, second edition, page 863) to destroy the brain and spinal cord of toads, open the chest cavity, expose the heart, and use a connected frog heart clip Clamp the apex of the heart in the diastolic phase, use a thread to ligate the left aorta 1cm away from the arterial sinus, lift the tie thread on the lef...

Embodiment 2

[0021] Embodiment two, ginsenoside Rh 2 Effects on Hemodynamics and Myocardial Contractility of Rabbit Heart in Vivo

[0022] 1. 24 New Zealand white rabbits, male or female, body weight 2-4Kg, were randomly divided into 3 groups, control group (normal saline), ginsenoside Ck group (40μg / kg) and ginsenoside Rh 2 group (40 μg / kg), 6 rats in each group.

[0023] 2. Methods: Rabbits were anesthetized by intravenous injection of pentobarbital sodium 30mg / kg, and tracheal intubation was performed. An epidural anesthesia tube filled with heparin solution was inserted from the left common carotid artery to the left ventricle, and the pressure signal was sent to a multichannel physiological recorder through a pressure transducer for recording and processing, and the pressure signal of the left femoral artery was guided in the same way. After the indicators were stable for more than 5 minutes, each drug was injected intravenously at a dose of 20 μg / kg, and each indicator was continuo...

Embodiment 3

[0027] Embodiment three, ginsenoside Rg 3 Observation on Clinical Curative Effect of Oral Administration on Congestive Heart Failure

[0028] 1. Materials and Methods 62 patients (35 males and 27 females) met the diagnostic criteria for congestive heart failure. Aged 40-59 (average 52) years old. According to NYHA classification: 26 cases of cardiac function grade II, 21 cases of grade III, and 15 cases of grade IV. Randomly divided into ginseng group saponin Rg 3 Compared with the conventional treatment group, the age, gender, underlying cause and echocardiographic indicators of the two groups of patients were basically similar, with no significant difference. After admission, the observation group took Shenyi capsule (containing ginsenoside Rg 3 20mg, produced by Jilin East Asia Pharmaceutical Co., Ltd.). 20mg each time, twice a day, 7 days as a course of treatment, other treatments are the same as the conventional treatment group. The conventional treatment group inc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the application of panaxoside Rh2, Ck and Rg3 to increase the heart contraction force, wherein the medicine compound comprises active panaxoside Rh2 and / or Ck and / or Rg3 and medicine carrier, to be made into injection, oral agent and film agent, to cure acute and low heart cardiac failure or reduced heart contraction force.

Description

technical field [0001] The present invention relates to ginsenoside Rh 2 , Ck and Rg 3 Use in increasing myocardial contractility. Background technique [0002] Ginseng has been used in my country for thousands of years and belongs to tonic medicine. According to the Pharmacopoeia, its functions and indications are "invigorating the vital energy, recovering the veins, strengthening the spleen and benefiting the lungs, promoting body fluid, and calming the nerves. It is used for body deficiency, cold limbs and weak pulse. Spleen deficiency eats less, lung deficiency coughs, fluid injury Thirst, internal heat and thirst, long-term illness and deficiency, palpitations and insomnia, impotence and uterine cold; heart failure, cardiogenic shock." In recent years, various monomer components of ginseng have been separated and purified. The biological effects of monomeric components have been gradually discovered, but the active ingredients of ginseng for the treatment of heart fa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K9/08A61K9/20A61K9/48A61P9/00A61P9/04
Inventor 彭康康马维富
Owner 彭康康
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap